Pharma Focus Asia

NSG BioLabs and Eppendorf Group Form Alliance to Enhance Biotech Support in Singapore

Thursday, June 13, 2024

NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, has announced a partnership with Eppendorf, a prominent global life science company. This partnership aims to support biotech startups by offering essential resources such as product and applications expertise and extensive networks to advance their research and development (R&D).

This collaboration will create an environment where NSG BioLabs' residents can thrive, providing them with exclusive access to Eppendorf's advanced equipment, consumables, and services. This access will enable residents to accelerate their research and expand their innovations, contributing to significant discoveries and advancements in life sciences.

Since its founding in 2019, NSG BioLabs has been helping innovators develop impactful solutions in sectors such as health, biomedical, agrifood, and industrial biotechnology. The company has supported work in precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other important fields. With the largest co-working biotech laboratory and office space in Singapore, NSG BioLabs has leveraged extensive networks with local and international partners, suppliers, and industry experts to support its residents. To date, NSG BioLabs has hosted over 40 companies, including several multi-billion-dollar multinationals and numerous promising startups that have achieved significant milestones. These startups have collectively raised nearly US$400 million in funding and created hundreds of jobs.

Daphne Teo, CEO and Founder of NSG BioLabs, expressed excitement about the partnership, saying, "We are thrilled to announce our strategic partnership with Eppendorf, a leader in life sciences equipment and services. At NSG BioLabs, fostering an environment where our residents can thrive is our top priority. This collaboration will provide our residents with exclusive access to Eppendorf's cutting-edge equipment, consumables, and services, empowering them to accelerate their research and scale their innovations. Together, we are shaping the future of life sciences and driving impactful discoveries."

Surendran Krishnamurthi, Managing Director of Eppendorf Southeast Asia, emphasized the importance of supporting biotech startups: "Empowering innovative biotech startups is of strategic importance to the Eppendorf Group, as they drive the future of medical innovation and the development of new treatments. Eppendorf's purpose is to help improve human living conditions, and we have been clearly committed for almost 80 years to supporting scientists around the world. Eppendorf is proud to engage in a partnership with NSG BioLabs, affirming our shared vision for supporting innovators in creating impactful biotech solutions. Being part of this scientific community is crucial, and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond."

Since its inception, NSG BioLabs has supported biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices, advanced equipment, and privileged access to service providers and suppliers. With three sites totaling 35,000 square feet located in the heart of Singapore's R&D ecosystem, NSG BioLabs is a key hub for biotech innovation. As one of the largest private biotech incubators in the region, and backed by strong partnerships and strategic investors such as Celadon Partners and ClavystBio, NSG BioLabs is well-positioned to enhance its offerings of infrastructure, services, and networks for its growing community.

Eppendorf is a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories worldwide. Its product portfolio includes pipettes, pipette tips, centrifuges, mixers, ultra-freezers, and bioreactors for cell and gene research, along with a wide range of high-quality consumables. In fiscal year 2023, the Eppendorf Group generated €1.08 billion in sales and invested €69 million in R&D.

Eppendorf products are used in various research laboratories, including those in the pharmaceutical, biotech, chemical, and food industries, as well as in clinical, environmental, forensic, and industrial laboratories. Since 1945, the Eppendorf Group has been headquartered in Hamburg, Germany, and now operates production and R&D sites in Europe, Asia, and North America, with subsidiaries in 33 countries. The Group employs over 5,000 people worldwide, all dedicated to improving human living conditions in line with the company's founding purpose.



magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference